Food and Drug Administration (FDA), the approved dosages for some of the commonly prescribed GLP-1 agonists are as follows: Semaglutide (Ozempic): 0.5 mg, 1 mg, or 2 mg once weekly for type 2 diabetes, and up to 2.4 mg once weekly for chronic weight management (marketed as Wegovy)
Bofanglutide is a biweekly (once every 2 weeks) injection, unlike most other GLP-1 medications (i.e., Ozempic, Wegovy, or Mounjaro), which are once-weekly shots
RCT, randomized controlled study
Other alternatives to Contrave or Wegovy include: Ozempic (semaglutide): once-weekly injection approved for people with type 2 diabetes, sometimes used off-label for weight loss Rybelsus (semaglutide): oral semaglutide tablet taken once daily Victoza ( liraglutide ): daily diabetes injection, available in a lower-cost generic version Metformin : generic diabetes medication that has shown modest amounts of weight loss in clinical studies , though it isnt approved for weight management
Who May Qualify for a GLP-1 Lawsuit You may qualify for a GLP-1 injury claim if you meet the following criteria: Medication: Use of a brand-name GLP-1 drug Ozempic, Wegovy, Mounjaro, Trulicity, or Rybelsus Duration: Used the medication for at least 23 months Purpose: Prescribed for weight loss or diabetes Injury: Gastroparesis a condition characterized by partial or complete paralysis of the stomach, leading to delayed gastric emptying Severe intestinal obstruction (ileus) a disruption of normal bowel function causing significant blockage of the intestines Gallbladder disease resulting in cholecystectomy (surgical removal of the gallbladder) prior to 2022 Treatment: Emergency room or hospital visit required Common GLP-1 Side Effects and Injuries While many patients tolerate GLP-1 receptor agonists well, others experience debilitating side effects such as chronic nausea, vomiting, abdominal pain, dehydration, and severe gastrointestinal distress
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake
